{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:15:32Z","timestamp":1792181732026,"version":"4.4.0"},"reference-count":210,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T00:00:00Z","timestamp":1676246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>The coronavirus disease (COVID-19) breakout had an unimaginable worldwide effect in the 21st century, claiming millions of lives and putting a huge burden on the global economy. The potential developments in vaccine technologies following the determination of the genetic sequence of SARS-CoV-2 and the increasing global efforts to bring potential vaccines and therapeutics into the market for emergency use have provided a small bright spot to this tragic event. Several intriguing vaccine candidates have been developed using recombinant technology, genetic engineering, and other vaccine development technologies. In the last decade, a vast amount of the vaccine development process has diversified towards the usage of viral vector-based vaccines. The immune response elicited by such vaccines is comparatively higher than other approved vaccine candidates that require a booster dose to provide sufficient immune protection. The non-replicating adenoviral vectors are promising vaccine carriers for infectious diseases due to better yield, cGMP-friendly manufacturing processes, safety, better efficacy, manageable shipping, and storage procedures. As of April 2022, the WHO has approved a total of 10 vaccines around the world for COVID-19 (33 vaccines approved by at least one country), among which three candidates are adenoviral vector-based vaccines. This review sheds light on the developmental summary of all the adenoviral vector-based vaccines that are under emergency use authorization (EUA) or in the different stages of development for COVID-19 management.<\/jats:p>","DOI":"10.3390\/vaccines11020432","type":"journal-article","created":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T02:41:56Z","timestamp":1676342516000},"page":"432","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":78,"title":["Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7701-8597","authenticated-orcid":false,"given":"Vivek","family":"Chavda","sequence":"first","affiliation":[{"name":"Department of Pharmaceutics and Pharmaceutical Technology, L. M. College of Pharmacy, Ahmedabad 380009, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajashri","family":"Bezbaruah","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Faculty of Science and Engineering, Dibrugarh University, Dibrugarh 786004, Assam, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Disha","family":"Valu","sequence":"additional","affiliation":[{"name":"Drug Product Development Laboratory, Biopharma Division, Intas Pharmaceutical Ltd., Moraiya, Ahmedabad 382213, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bindra","family":"Patel","sequence":"additional","affiliation":[{"name":"Pharmacy Section, L. M. College of Pharmacy, Ahmedabad 380009, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9308-4394","authenticated-orcid":false,"given":"Anup","family":"Kumar","sequence":"additional","affiliation":[{"name":"Pharmacy Section, L. M. College of Pharmacy, Ahmedabad 380009, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Prasad","sequence":"additional","affiliation":[{"name":"Cell and Gene Therapy Drug Product Development Laboratory, Biopharma Division, Intas Pharmaceutical Ltd., Moraiya, Ahmedabad 382213, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bibhuti","family":"Kakoti","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Faculty of Science and Engineering, Dibrugarh University, Dibrugarh 786004, Assam, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4206-1541","authenticated-orcid":false,"given":"Ajeet","family":"Kaushik","sequence":"additional","affiliation":[{"name":"NanoBioTech Laboratory, Health Systems Engineering, Department of Environmental Engineering, Florida Polytechnic University, Lakeland, FL 33805-8531, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariya","family":"Jesawadawala","sequence":"additional","affiliation":[{"name":"Pharmacy Section, L. M. College of Pharmacy, Ahmedabad 380009, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,13]]},"reference":[{"key":"ref_1","first-page":"100013","article-title":"Darunavir ethanolate: Repurposing an anti-HIV drug in COVID-19 treatment","volume":"3","author":"Chavda","year":"2021","journal-title":"Eur. J. Med. Chem. Rep."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Gralinski, L.E., and Menachery, V.D. (2020). Return of the coronavirus: 2019-nCoV. Viruses, 12.","DOI":"10.3390\/v12020135"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1473-3099(20)30243-7","article-title":"Estimates of the severity of coronavirus disease 2019: A model-based analysis","volume":"20","author":"Verity","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.bjid.2020.06.002","article-title":"Ivermectin: Potential candidate for the treatment of COVID-19","volume":"24","author":"Gupta","year":"2020","journal-title":"Braz. J. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.3389\/fimmu.2020.01712","article-title":"The Potential Impact of Zinc Supplementation on COVID-19 Pathogenesis","volume":"11","author":"Wessels","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.ygeno.2020.09.059","article-title":"Genetics and genomics of SARS-CoV-2: A review of the literature with the special focus on genetic diversity and SARS-CoV-2 genome detection","volume":"113","author":"Rahimi","year":"2021","journal-title":"Genomics"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Vilar, S., and Isom, D.G. (2021). One Year of SARS-CoV-2: How Much Has the Virus Changed?. Biology, 10.","DOI":"10.3390\/biology10020091"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"111518","DOI":"10.1016\/j.biopha.2021.111518","article-title":"Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy","volume":"138","author":"Mirtaleb","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"108393","DOI":"10.1016\/j.clim.2020.108393","article-title":"The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China","volume":"214","author":"Zhang","year":"2020","journal-title":"Clin. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"100086","DOI":"10.1016\/j.crphar.2022.100086","article-title":"Therapeutics for COVID-19 and post COVID-19 complications: An update","volume":"3","author":"Basu","year":"2022","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2217\/imt-2021-0168","article-title":"A global picture: Therapeutic perspectives for COVID-19","volume":"14","author":"Chavda","year":"2022","journal-title":"Immunotherapy"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"585354","DOI":"10.3389\/fimmu.2020.585354","article-title":"A Review of the Progress and Challenges of Developing a Vaccine for COVID-19","volume":"11","author":"Sharma","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3389\/fnano.2020.571284","article-title":"Grand Challenges in Bio-Nanotechnology to Manage the COVID-19 Pandemic","volume":"2","author":"Paliwal","year":"2020","journal-title":"Front. Nanotechnol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"100363","DOI":"10.1016\/j.cobme.2021.100363","article-title":"Antibacterial and antiviral high-performance nano-systems to mitigate new SARS-CoV-2 variants of concerns","volume":"21","author":"Tiwari","year":"2021","journal-title":"Curr. Opin. Biomed. Eng."},{"key":"ref_15","unstructured":"(2022, January 26). WHO COVID-19 Vaccine Tracker and Landscape. Available online: https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1016\/S0140-6736(21)02758-6","article-title":"Omicron SARS-CoV-2 variant: A new chapter in the COVID-19 pandemic","volume":"398","author":"Karim","year":"2021","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.maturitas.2022.01.011","article-title":"Omicron Variant (B.1.1.529) of SARS-CoV-2: Threat for the elderly?","volume":"158","author":"Chavda","year":"2022","journal-title":"Maturitas"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Chavda, V.P., and Apostolopoulos, V. (2022). Is Booster Dose Strategy Sufficient for Omicron Variant of SARS-CoV-2?. Vaccines, 10.","DOI":"10.3390\/vaccines10030367"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1080\/14760584.2022.2044800","article-title":"Global impact of delta plus variant and vaccination","volume":"21","author":"Chavda","year":"2022","journal-title":"Expert Rev. Vaccines"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ijid.2021.11.040","article-title":"Emergence of new SARS-CoV-2 Variant of Concern Omicron (B.1.1.529)\u2014highlights Africa\u2019s research capabilities, but exposes major knowledge gaps, inequities of vaccine distribution, inadequacies in global COVID-19 response and control efforts","volume":"114","author":"Petersen","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41577-020-00480-0","article-title":"Viral targets for vaccines against COVID-19","volume":"21","author":"Dai","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Chavda, V.P., Bezbaruah, R., Athalye, M., Parikh, P.K., Chhipa, A.S., Patel, S., and Apostolopoulos, V. (2022). Replicating Viral Vector-Based Vaccines for COVID-19: Potential Avenue in Vaccination Arena. Viruses, 14.","DOI":"10.3390\/v14040759"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41541-021-00292-w","article-title":"SARS-CoV-2 vaccines strategies: A comprehensive review of phase 3 candidates","volume":"6","author":"Kyriakidis","year":"2021","journal-title":"Npj Vaccines"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1080\/21645515.2019.1649532","article-title":"Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens","volume":"15","author":"Fathi","year":"2019","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"100009","DOI":"10.1016\/j.jvacx.2019.100009","article-title":"rVSV\u0394G-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk\/benefit assessment","volume":"1","author":"Monath","year":"2019","journal-title":"Vaccine X"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.coi.2011.03.006","article-title":"Viral vectors as vaccine platforms: Deployment in sight","volume":"23","author":"Rollier","year":"2011","journal-title":"Curr. Opin. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"6436","DOI":"10.1016\/j.vaccine.2016.06.059","article-title":"Vector-based genetically modified vaccines: Exploiting Jenner\u2019s legacy","volume":"34","author":"Ramezanpour","year":"2016","journal-title":"Vaccine"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.copbio.2007.10.010","article-title":"Replicating and non-replicating viral vectors for vaccine development","volume":"18","year":"2007","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_29","unstructured":"(2022, December 19). COVID-19 Vaccines with WHO Emergency Use Listing. Available online: https:\/\/extranet.who.int\/pqweb\/vaccines\/vaccinescovid-19-vaccine-eul-issued."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.gendis.2017.04.001","article-title":"Adenovirus-mediated gene delivery: Potential applications for gene and cell-based therapies in the new era of personalized medicine","volume":"4","author":"Lee","year":"2017","journal-title":"Genes Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/hum.2013.2527","article-title":"Adenovirus: The first effective in vivo gene delivery vector","volume":"25","author":"Crystal","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1134\/S0006297916070063","article-title":"Viral vectors for gene therapy: Current state and clinical perspectives","volume":"81","author":"Lukashev","year":"2016","journal-title":"Biochem. Mosc."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3389\/fimmu.2020.00909","article-title":"Factors Which Contribute to the Immunogenicity of Non-replicating Adenoviral Vectored Vaccines","volume":"11","author":"Coughlan","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1080\/21645515.2017.1383575","article-title":"Chimpanzee adenoviral vectors as vaccines for outbreak pathogens","volume":"13","author":"Ewer","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1556\/EuJMI.4.2014.1.2","article-title":"Human adenovirus: Viral pathogen with increasing importance","volume":"4","author":"Ghebremedhin","year":"2014","journal-title":"Eur. J. Microbiol. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.vaccine.2020.12.017","article-title":"Critical aspects of packaging, storage, preparation, and administration of mRNA and adenovirus-vectored COVID-19 vaccines for optimal efficacy","volume":"39","author":"Holm","year":"2021","journal-title":"Vaccine"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1097\/JOM.0000000000000879","article-title":"Risks Associated With Lentiviral Vector Exposures and Prevention Strategies","volume":"58","author":"Schlimgen","year":"2016","journal-title":"J. Occup. Environ. Med."},{"key":"ref_38","unstructured":"Raikwar, S.P., Kao, C.H., and Gardner, T.A. (2002). Adenoviral Vectors for Gene Therapy, Academic Press."},{"key":"ref_39","first-page":"163","article-title":"Single-cycle adenovirus vectors in the current vaccine landscape","volume":"17","author":"Barry","year":"2018","journal-title":"Expert Rev. Vaccines"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.omtm.2019.11.001","article-title":"Immunology of Adenoviral Vectors in Cancer Therapy","volume":"15","author":"Shaw","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S1473-3099(20)30019-0","article-title":"Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in Africa: A randomised, observer-blind, placebo-controlled, phase 2 trial","volume":"20","author":"Tapia","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1128\/CVI.00144-09","article-title":"Safety and immunogenicity of the merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adults","volume":"16","author":"Harro","year":"2009","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Steffen, T., Hassert, M., Hoft, S., Stone, E.T., Zhang, J., Geerling, E., Grimberg, B.T., Roberts, M.S., Pinto, A.K., and Brien, J.D. (2020). Immunogenicity and efficacy of a recombinant human adenovirus type 5 vaccine against Zika virus. Vaccines, 8.","DOI":"10.3390\/vaccines8020170"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"6990","DOI":"10.1016\/j.vaccine.2017.10.066","article-title":"A potent malaria vaccine based on adenovirus with dual modifications at Hexon and pVII","volume":"35","author":"Shiratsuchi","year":"2017","journal-title":"Vaccine"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/S1473-3099(20)30515-6","article-title":"Vaccine innovation spurred by the long wait for an Ebola virus vaccine","volume":"21","author":"Kobinger","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Daussy, C.F., Pied, N., and Wodrich, H. (2021). Understanding Post Entry Sorting of Adenovirus Capsids; A Chance to Change Vaccine Vector Properties. Viruses, 13.","DOI":"10.3390\/v13071221"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nrmicro3067","article-title":"Breaking and joining single-stranded DNA: The HUH endonuclease superfamily","volume":"11","author":"Chandler","year":"2013","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41541-020-00243-x","article-title":"Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses","volume":"5","author":"Bos","year":"2020","journal-title":"Npj Vaccines"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"6732","DOI":"10.1128\/JVI.79.11.6732-6740.2005","article-title":"Role of the E1--E4 protein in the differentiation-dependent life cycle of human papillomavirus type 31","volume":"79","author":"Wilson","year":"2005","journal-title":"J. Virol."},{"key":"ref_50","first-page":"3","article-title":"Improvements in gene therapy: Averting the immune response to adenoviral vectors","volume":"16","author":"Ritter","year":"2002","journal-title":"BioDrugs Clin. Immunother. Biopharm. Gene Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"6048","DOI":"10.1128\/JVI.73.7.6048-6055.1999","article-title":"Generation of an adenovirus vector lacking E1, e2a, E3, and all of E4 except open reading frame 3","volume":"73","author":"Gorziglia","year":"1999","journal-title":"J. Virol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Ricobaraza, A., Gonzalez-Aparicio, M., Mora-Jimenez, L., Lumbreras, S., and Hernandez-Alcoceba, R. (2020). High-Capacity Adenoviral Vectors: Expanding the Scope of Gene Therapy. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21103643"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1038\/sj.gt.3302612","article-title":"Gutless adenovirus: Last-generation adenovirus for gene therapy","volume":"12","author":"Alba","year":"2005","journal-title":"Gene Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3389\/fmicb.2014.00172","article-title":"Recombinant protein expression in Escherichia coli: Advances and challenges","volume":"5","author":"Rosano","year":"2014","journal-title":"Front. Microbiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2174\/1566523213666131125095046","article-title":"Adenovirus vectors for gene therapy, vaccination and cancer gene therapy","volume":"13","author":"Wold","year":"2013","journal-title":"Curr. Gene Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/sj.gt.3301301","article-title":"Production of first generation adenovirus vectors: A review","volume":"7","author":"Danthinne","year":"2000","journal-title":"Gene Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3389\/fonc.2019.00297","article-title":"Gene Therapy Leaves a Vicious Cycle","volume":"9","author":"Goswami","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"S169","DOI":"10.1006\/mthe.2000.0167","article-title":"DNA Virus Vectors II","volume":"1","author":"Duan","year":"2000","journal-title":"Mol. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12985-016-0576-5","article-title":"Cloning and rescue of the genome of Bombyx mori bidensovirus, and characterization of a recombinant virus","volume":"13","author":"Zhang","year":"2016","journal-title":"Virol. J."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1089\/hum.1996.7.17-2101","article-title":"Quantitative analysis of the packaging capacity of recombinant adeno-associated virus","volume":"7","author":"Dong","year":"1996","journal-title":"Hum. Gene Ther."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Rosewell, A., Vetrini, F., and Ng, P. (2011). Helper-Dependent Adenoviral Vectors. J. Genet. Syndr. Gene Ther., 1.","DOI":"10.4172\/2157-7412.S5-001"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"17771","DOI":"10.1038\/s41598-017-17651-0","article-title":"Site-specific chromosomal gene insertion: Flp recombinase versus Cas9 nuclease","volume":"7","author":"Phan","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1002\/jmv.27717","article-title":"SARS-CoV-2 variants and vulnerability at the global level","volume":"94","author":"Chavda","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1099\/vir.0.81579-0","article-title":"Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus","volume":"87","author":"See","year":"2006","journal-title":"J. Gen. Virol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.3389\/fimmu.2020.01581","article-title":"COVID-19 Coronavirus Vaccine Design Using Reverse Vaccinology and Machine Learning","volume":"11","author":"Ong","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"16030","DOI":"10.1038\/mtm.2016.30","article-title":"Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens","volume":"3","author":"Afkhami","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_67","first-page":"49","article-title":"Viral expression cassette elements to enhance transgene target specificity and expression in gene therapy","volume":"19","author":"Powell","year":"2015","journal-title":"Discov. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1080\/14760584.2021.1987223","article-title":"DNA vaccines for SARS-CoV-2: Towards third generation vaccination era","volume":"20","author":"Chavda","year":"2021","journal-title":"Expert Rev. Vaccines"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Chavda, V.P., Hossain, M.K., Beladiya, J., and Apostolopoulos, V. (2021). Nucleic Acid Vaccines for COVID-19: A Paradigm Shift in the Vaccine Development Arena. Biologics, 1.","DOI":"10.3390\/biologics1030020"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"576622","DOI":"10.3389\/fimmu.2020.576622","article-title":"The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens","volume":"11","author":"Duan","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3389\/fmolb.2020.591873","article-title":"Spike Proteins of SARS-CoV and SARS-CoV-2 Utilize Different Mechanisms to Bind With Human ACE2","volume":"7","author":"Xie","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1089\/hum.2013.235","article-title":"Adenovirus-based vaccines for fighting infectious diseases and cancer: Progress in the field","volume":"25","author":"Majhen","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3390\/vaccines2030624","article-title":"Developments in Viral Vector-Based Vaccines","volume":"2","author":"Ura","year":"2014","journal-title":"Vaccines"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A guide to vaccinology: From basic principles to new developments","volume":"21","author":"Pollard","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3389\/fmolb.2021.635337","article-title":"Developmental Landscape of Potential Vaccine Candidates Based on Viral Vector for Prophylaxis of COVID-19","volume":"8","author":"Bezbaruah","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1089\/hum.2011.2517","article-title":"Adenovirus: Teaching an old dog new tricks","volume":"22","author":"Seymour","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3389\/fncel.2018.00027","article-title":"Revisiting the Role of Clathrin-Mediated Endoytosis in Synaptic Vesicle Recycling","volume":"12","author":"Milosevic","year":"2018","journal-title":"Front. Cell Neurosci."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.2147\/IDR.S315727","article-title":"Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety","volume":"14","author":"Mascellino","year":"2021","journal-title":"Infect. Drug Resist."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3389\/fmicb.2015.00467","article-title":"Nuclear entry of DNA viruses","volume":"6","author":"Fay","year":"2015","journal-title":"Front. Microbiol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e2116147118","DOI":"10.1073\/pnas.2116147118","article-title":"A class II MHC-targeted vaccine elicits immunity against SARS-CoV-2 and its variants","volume":"118","author":"Pishesha","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41541-021-00356-x","article-title":"Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic","volume":"6","author":"Lorincz","year":"2021","journal-title":"Npj Vaccines"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4103\/0974-777X.77299","article-title":"Fundamentals of vaccine immunology","volume":"3","author":"Clem","year":"2011","journal-title":"J. Glob. Infect. Dis."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1038\/s41467-020-18077-5","article-title":"An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques","volume":"11","author":"Feng","year":"2020","journal-title":"Nat. Common."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.chom.2020.07.018","article-title":"Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in Mice","volume":"28","author":"Case","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/imm.12829","article-title":"Novel viral vectors in infectious diseases","volume":"153","author":"Humphreys","year":"2018","journal-title":"Immunology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"633946","DOI":"10.3389\/fmicb.2021.633946","article-title":"Codon Usage and Adenovirus Fitness: Implications for Vaccine Development","volume":"12","author":"Alemany","year":"2021","journal-title":"Front. Microbiol."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Rijkers, G.T., Weterings, N., Obregon-Henao, A., Lepolder, M., Dutt, T.S., van Overveld, F.J., and Henao-Tamayo, M. (2021). Antigen Presentation of mRNA-Based and Virus-Vectored SARS-CoV-2 Vaccines. Vaccines, 9.","DOI":"10.3390\/vaccines9080848"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.3389\/fimmu.2020.01949","article-title":"Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past","volume":"11","author":"Shah","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1111\/all.14364","article-title":"Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19","volume":"75","author":"Azkur","year":"2020","journal-title":"Allergy"},{"key":"ref_90","unstructured":"(2022, December 22). Worldo meter. COVID-19: CORONAVIRUS PANDEMIC. Available online: https:\/\/www.worldometers.info\/coronavirus\/."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Lundstrom, K. (2020). Coronavirus Pandemic\u2014Therapy and Vaccines. Biomedicines, 8.","DOI":"10.3390\/biomedicines8050109"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Liu, Y., and Ye, Q. (2022). Safety and Efficacy of the Common Vaccines against COVID-19. Vaccines, 10.","DOI":"10.3390\/vaccines10040513"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41541-021-00327-2","article-title":"Strategy for COVID-19 vaccination in India: The country with thesecond highest population and number of cases","volume":"6","author":"Kumar","year":"2021","journal-title":"Npj Vaccines"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet Lond. Engl."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"ref_96","unstructured":"US. National Library of Medicine (2020). Phase III Double-Blind, Placebo-Controlled Study of AZD1222 for the Prevention of COVID-19 in Adults, ClinicalTrials.gov."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s13577-021-00512-4","article-title":"COVID-19 vaccines: Rapid development, implications, challenges and future prospects","volume":"34","author":"Kashte","year":"2021","journal-title":"Hum. Cell"},{"key":"ref_98","unstructured":"(2022, December 22). McGill COVID19 Vaccine Tracker Team COVID-19 VACCINE TRACKER. Available online: https:\/\/covid19.trackvaccines.org\/."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/s41591-021-01408-4","article-title":"First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland","volume":"27","author":"Simpson","year":"2021","journal-title":"Nat. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(21)00432-3","article-title":"Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: A pooled analysis of four randomised trials","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"100278","DOI":"10.1016\/j.lanepe.2021.100278","article-title":"Impact of SARS-CoV-2 Delta variant on incubation, transmission settings and vaccine effectiveness: Results from a nationwide case-control study in France","volume":"13","author":"Grant","year":"2021","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"4598","DOI":"10.1038\/s41467-021-24909-9","article-title":"Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants","volume":"12","author":"Ikegame","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_103","first-page":"887","article-title":"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: Two open, non-randomised phase 1\/2 studies from Russia","volume":"396","author":"Babira","year":"2020","journal-title":"Cross Mark"},{"key":"ref_104","unstructured":"(2022, December 22). Second Interim Analysis of Clinical Trial Data Showed a 91.4% Efficacy for the Sputnik V Vaccine on Day 28 after the First Dose; Vaccine Efficacy Is over 95% 42 Days after the First Dose. Official Website Vaccine against COVID-19 Sputnik V. Available online: https:\/\/sputnikvaccine.com\/newsroom\/pressreleases\/second-interim-analysis-of-clinical-trial-data-showed-a-91-4-efficacy-for-the-sputnik-v-vaccine-on-d\/."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"101126","DOI":"10.1016\/j.eclinm.2021.101126","article-title":"Effectiveness of the first component of Gam-COVID-Vac (Sputnik V) on reduction of SARS-CoV-2 confirmed infections, hospitalisations and mortality in patients aged 60\u201379: A retrospective cohort study in Argentina","volume":"40","author":"Olszevicki","year":"2021","journal-title":"EClinicalMedicine"},{"key":"ref_106","unstructured":"FDA (2022). Janssen COVID-19 Vaccine, FDA."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: A randomised, double-blind, placebo- controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"ref_109","unstructured":"US. National Library of Medicine (2020). Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above, ClinicalTrials.gov."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1473-3099(21)00396-0","article-title":"Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: Preliminary report of an open-label and randomised phase 1 clinical trial","volume":"21","author":"Wu","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_111","unstructured":"US. National Library of Medicine (2021). Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-S against COVID-19, ClinicalTrials.gov."},{"key":"ref_112","unstructured":"US. National Library of Medicine (2021). A Synthetic MVA-Based SARS-CoV-2 Vaccine, COH04S1, for the Prevention of COVID-19\u2014Full Text View, ClinicalTrials.gov."},{"key":"ref_113","unstructured":"US. National Library of Medicine (2020). Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine, ClinicalTrials.gov."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia","volume":"397","author":"Logunov","year":"2021","journal-title":"Lancet Lond. Engl."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/S0140-6736(21)00894-1","article-title":"V Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial \u2013 Authors\u2019 reply","volume":"397","author":"Logunov","year":"2021","journal-title":"Lancet"},{"key":"ref_116","unstructured":"US. National Library of Medicine (2020). GRAd-COV2 Vaccine AGAINST COVID-19, ClinicalTrials.gov."},{"key":"ref_117","unstructured":"US. National Library of Medicine (2021). Study of GRAd-COV2 for the Prevention of COVID-19 in Adults, ClinicalTrials.gov."},{"key":"ref_118","unstructured":"US. National Library of Medicine (2021). An Open Study on the Safety, Tolerability, and Immunogenicity of \u201cSputnik Light\u201d Vaccine, ClinicalTrials.gov."},{"key":"ref_119","unstructured":"US. National Library of Medicine (2021). Study to Evaluate Efficacy, Immunogenicity and Safety of the Sputnik-Light, ClinicalTrials.gov."},{"key":"ref_120","unstructured":"Ramvikas, M., Arumugam, M., Chakrabarti, S.R., and Jaganathan, K.S. (2017). Micro and Nanotechnology in Vaccine Development, Elsevier."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1016\/j.drudis.2021.07.021","article-title":"Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management","volume":"26","author":"Chavda","year":"2021","journal-title":"Drug Discov. Today"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.3389\/fimmu.2020.611337","article-title":"Mucosal Immunity in COVID-19: A Neglected but Critical Aspect of SARS-CoV-2 Infection","volume":"11","author":"Russell","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41564-020-0688-y","article-title":"Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses","volume":"5","author":"Letko","year":"2020","journal-title":"Nat. Microbiol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.apsb.2020.02.008","article-title":"Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods","volume":"10","author":"Wu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"100004","DOI":"10.1016\/j.ccmp.2021.100004","article-title":"COVAX-19\u00ae Vaccine: Completely blocks virus transmission to non-immune individuals","volume":"1","author":"Chavda","year":"2021","journal-title":"Clin. Complement. Med. Pharmacol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.cell.2020.05.042","article-title":"SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract","volume":"182","author":"Hou","year":"2020","journal-title":"Cell"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"eabh0755","DOI":"10.1126\/scitranslmed.abh0755","article-title":"Intranasal ChAdOx1 nCoV-19\/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models","volume":"13","author":"Purushotham","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"109452","DOI":"10.1016\/j.celrep.2021.109452","article-title":"An intranasal vaccine durably protects against SARS-CoV-2 variants in mice","volume":"36","author":"Hassan","year":"2021","journal-title":"Cell Rep."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"King, R.G., Silva-Sanchez, A., Peel, J.N., Botta, D., Meza-Perez, S., Allie, R., Schultz, M.D., Liu, M., Bradley, J.E., and Qiu, S. (2020). Single-dose intranasal administration of AdCOVID elicits systemic and mucosal immunity against SARS-CoV-2 in mice. BioRxiv Prepr. Serv. Biol.","DOI":"10.1101\/2020.10.10.331348"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Van Doremalen, N., Purushotham, J., Schulz, J., Holbrook, M., Bushmaker, T., Carmody, A., Port, J., Yinda, K.C., Okumura, A., and Saturday, G. (2021). Intranasal ChAdOx1 nCoV-19\/AZD1222 vaccination reduces shedding of SARS-CoV-2 D614G in rhesus macaques. BioRxiv Prepr. Serv. Biol.","DOI":"10.1101\/2021.01.09.426058"},{"key":"ref_131","first-page":"1138","article-title":"COVID-19 Vaccine Nasal Spray","volume":"326","author":"Rubin","year":"2021","journal-title":"JAMA"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"100230","DOI":"10.1016\/j.xcrm.2021.100230","article-title":"A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques","volume":"2","author":"Hassan","year":"2021","journal-title":"Cell Rep. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1038\/s41467-020-17972-1","article-title":"A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge","volume":"11","author":"Wu","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_134","unstructured":"(2022, November 06). NMPA Approves the Application for Conditional Marketing. Available online: https:\/\/www.lillyasiaventures.com\/blog\/nmpa-approves-the-application-for-conditional-marketing-authorization-of."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.cell.2020.06.043","article-title":"Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus","volume":"182","author":"Korber","year":"2020","journal-title":"Cell"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.cell.2020.06.040","article-title":"Making Sense of Mutation: What D614G Means for the COVID-19 Pandemic Remains Unclear","volume":"182","author":"Grubaugh","year":"2020","journal-title":"Cell"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"e00647-20","DOI":"10.1128\/JVI.00647-20","article-title":"The Nucleocapsid Protein of SARS\u2013CoV-2: A Target for Vaccine Development","volume":"94","author":"Dutta","year":"2020","journal-title":"J. Virol."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Rice, A., Verma, M., Shin, A., Zakin, L., Sieling, P., Tanaka, S., Adisetiyo, H., Taft, J., Patel, R., and Buta, S. (2020). A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses. bioRxiv.","DOI":"10.1101\/2020.07.29.227595"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"5713","DOI":"10.1002\/jmv.28044","article-title":"Effects of boosted mRNA and adenoviral-vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac\/AZD1222 vaccination","volume":"94","author":"Suntronwong","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_140","unstructured":"(2022, November 06). Heterologous Booster with Inhaled Adenovirus Vector Vaccine Expected to Be an Effective Strategy in Preventing Omicron Variant BA.5: Research\u2014Global Times. Available online: https:\/\/www.globaltimes.cn\/page\/202210\/1277116.shtml."},{"key":"ref_141","first-page":"1824","article-title":"Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review","volume":"323","author":"Sanders","year":"2020","journal-title":"JAMA"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"12125","DOI":"10.1128\/JVI.79.19.12125-12131.2005","article-title":"Adenovirus receptors","volume":"79","author":"Zhang","year":"2005","journal-title":"J. Virol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1586\/erv.09.29","article-title":"Strategies to overcome host immunity to adenovirus vectors in vaccine development","volume":"8","author":"Thacker","year":"2009","journal-title":"Expert Rev. Vaccines"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.3389\/fimmu.2018.01963","article-title":"New Vaccine Technologies to Combat Outbreak Situations","volume":"9","author":"Rauch","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1016\/j.vaccine.2007.01.064","article-title":"Attenuated measles virus as a vaccine vector","volume":"25","author":"Zuniga","year":"2007","journal-title":"Vaccine"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s11262-017-1486-3","article-title":"Vaccine platform recombinant measles virus","volume":"53","year":"2017","journal-title":"Virus Genes"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1473-3099(15)70043-5","article-title":"Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: A randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial","volume":"15","author":"Ramsauer","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/oxfordjournals.bmb.a072951","article-title":"Adenovirus and adeno-associated virus mediated gene transfer","volume":"51","author":"Kremer","year":"1995","journal-title":"Br. Med. Bull."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1128\/CMR.00052-07","article-title":"Adenoviruses in immunocompromised hosts","volume":"21","year":"2008","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1016\/j.vaccine.2011.05.025","article-title":"International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations","volume":"29","author":"Barouch","year":"2011","journal-title":"Vaccine"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1099\/0022-1317-83-1-151","article-title":"Chimpanzee adenovirus CV-68 adapted as a gene delivery vector interacts with the coxsackievirus and adenovirus receptor","volume":"83","author":"Cohen","year":"2002","journal-title":"J. Gen. Virol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"11603","DOI":"10.1128\/JVI.75.23.11603-11613.2001","article-title":"Replication-Defective Vector Based on a Chimpanzee Adenovirus","volume":"75","author":"Farina","year":"2001","journal-title":"J. Virol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1089\/10430349950018021","article-title":"PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo","volume":"10","author":"Lachapelle","year":"1999","journal-title":"Hum. Gene Ther."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1016\/j.biomaterials.2011.11.020","article-title":"Enhancing the therapeutic efficacy of adenovirus in combination with biomaterials","volume":"33","author":"Kim","year":"2012","journal-title":"Biomaterials"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1038\/sj.gt.3301858","article-title":"Encapsulation of recombinant adenovirus into alginate microspheres circumvents vector specific immune response","volume":"9","author":"Sailaja","year":"2002","journal-title":"Gene Ther."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.idnow.2021.02.007","article-title":"COVID-19 vaccines: Frequently asked questions and updated answers","volume":"51","author":"Lefebvre","year":"2021","journal-title":"Infect. Dis. Now"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"10780","DOI":"10.1128\/JVI.77.20.10780-10789.2003","article-title":"Oral Vaccination of Mice with Adenoviral Vectors Is Not Impaired by Preexisting Immunity to the Vaccine Carrier","volume":"77","author":"Xiang","year":"2003","journal-title":"J. Virol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1177\/0194599820933170","article-title":"Intranasal Antiviral Drug Delivery and Coronavirus Disease 2019 (COVID-19): A State of the Art Review","volume":"163","author":"Higgins","year":"2020","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/1521-2254(200009\/10)2:5<308::AID-JGM131>3.0.CO;2-3","article-title":"Lentiviral vectors: Excellent tools for experimental gene transfer and promising candidates for gene therapy","volume":"2","author":"Vigna","year":"2000","journal-title":"J. Gene Med."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3389\/fbioe.2020.00368","article-title":"Production of Vesicular Stomatitis Virus Glycoprotein-Pseudotyped Lentiviral Vector Is Enhanced by Ezrin Silencing","volume":"8","author":"Izumida","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.chom.2020.12.010","article-title":"Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models","volume":"29","author":"Ku","year":"2021","journal-title":"Cell Host Microbe"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.3389\/fimmu.2019.02631","article-title":"Heterologous Immunity: Role in Natural and Vaccine-Induced Resistance to Infections","volume":"10","author":"Agrawal","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.3389\/fimmu.2020.586984","article-title":"Potential Cross-Reactive Immunity to SARS-CoV-2 From Common Human Pathogens and Vaccines","volume":"11","author":"Reche","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"M\u00f6ller, J., Kraner, M.E., and Burkovski, A. (2019). More than a toxin: Protein inventory of Clostridium tetani toxoid vaccines. Proteomes, 7.","DOI":"10.3390\/proteomes7020015"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1016\/j.vaccine.2019.04.059","article-title":"Proteomics of diphtheria toxoid vaccines reveals multiple proteins that are immunogenic and may contribute to protection of humans against Corynebacterium diphtheriae","volume":"37","author":"Kraner","year":"2019","journal-title":"Vaccine"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41421-021-00360-4","article-title":"Heterologous prime-boost immunizations with chimpanzee adenoviral vectors elicit potent and protective immunity against SARS-CoV-2 infection","volume":"7","author":"Liu","year":"2021","journal-title":"Cell Discov."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1056\/NEJMc2105869","article-title":"Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination","volume":"384","author":"Muir","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1056\/NEJMe2106315","article-title":"SARS-CoV-2 Vaccine\u2013Induced Immune Thrombotic Thrombocytopenia","volume":"384","author":"Cines","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/pgmj.2007.059188","article-title":"Heparin Induced Thrombocytopenia: Diagnosis and Management Update","volume":"83","author":"Ahmed","year":"2007","journal-title":"Postgrad. Med. J."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1182\/blood.2021012938","article-title":"Anti\u2013platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein","volume":"138","author":"Greinacher","year":"2021","journal-title":"Blood"},{"key":"ref_172","unstructured":"(2022, November 06). Towards Understanding ChAdOx1 nCov-19 Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT)\u2014ISTH Congress Abstracts. Available online: https:\/\/abstracts.isth.org\/abstract\/towards-understanding-chadox1-ncov-19-vaccine-induced-immune-thrombotic-thrombocytopenia-vitt\/."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"e78513","DOI":"10.7554\/eLife.78513","article-title":"Process-related impurities in the ChAdOx1 nCov-19 vaccine","volume":"11","author":"Krutzke","year":"2021","journal-title":"eLife"},{"key":"ref_174","unstructured":"(2023, January 21). Vaccine Safety Datalink (VSD)|VSD|Monitoring|Ensuring Safety|Vaccine Safety|CDC. Available online: https:\/\/www.cdc.gov\/vaccinesafety\/ensuringsafety\/monitoring\/vsd\/index.html."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"956825","DOI":"10.3389\/fimmu.2022.956825","article-title":"Capillary leak syndrome following COVID-19 vaccination: Data from the European pharmacovigilance database Eudravigilance","volume":"13","author":"Ruggiero","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"977","DOI":"10.15585\/mmwr.mm7027e2","article-title":"Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices\u2014United States, June 2021","volume":"70","author":"Gargano","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1056\/NEJMoa2105290","article-title":"Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 NCoV-19) Covid-19 Vaccine","volume":"385","author":"Falsey","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_178","unstructured":"(2023, January 21). Selected Adverse Events Reported after COVID-19 Vaccination | CDC. Available online: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/safety\/adverse-events.html."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"513","DOI":"10.7326\/M21-4502","article-title":"Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination\u2014United States, December 2020 to August 2021","volume":"175","author":"See","year":"2022","journal-title":"Ann. Intern. Med."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/jama.2021.24110","article-title":"Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021","volume":"327","author":"Oster","year":"2022","journal-title":"JAMA"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa030595","article-title":"Use of the inactivated intranasal influenza vaccine and the risk of Bell\u2019s palsy in Switzerland","volume":"350","author":"Mutsch","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"120686","DOI":"10.1016\/j.ijpharm.2021.120686","article-title":"Nasal vaccination against SARS-CoV-2: Synergistic or alternative to intramuscular vaccines ?","volume":"603","author":"Tiboni","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/s44161-022-00177-8","article-title":"Apparent risks of postural orthostatic tachycardia syndrome diagnoses after COVID-19 vaccination and SARS-Cov-2 Infection","volume":"1","author":"Kwan","year":"2022","journal-title":"Nat. Cardiovasc. Res."},{"key":"ref_184","unstructured":"(2022, December 20). Ewen Callaway, The coronavirus is mutating\u2014Does it matter?. Available online: https:\/\/www.nature.com\/articles\/d41586-020-02544-6."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/s41591-022-01699-1","article-title":"Effectiveness of COVID-19 booster vaccines against covid-19 related symptoms, hospitalisation and death in England","volume":"28","author":"Andrews","year":"2022","journal-title":"Nat. Med."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(21)02249-2","article-title":"Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: An observational study","volume":"398","author":"Barda","year":"2021","journal-title":"Lancet"},{"key":"ref_187","doi-asserted-by":"crossref","unstructured":"Andrews, N., Stowe, J., Kirsebom, F., Gower, C., Ramsay, M., and Bernal, J.L. (2021). Effectiveness of BNT162b2 (Comirnaty, Pfizer-BioNTech) COVID-19 booster vaccine against covid-19 related symptoms in England: Test negative case-control study. medRxiv.","DOI":"10.1101\/2021.11.15.21266341"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/ni.2039","article-title":"Immunological mechanisms of vaccination","volume":"12","author":"Pulendran","year":"2011","journal-title":"Nat. Immunol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"100208","DOI":"10.1016\/j.lanepe.2021.100208","article-title":"Dynamics of antibody response to BNT162b2 vaccine after six months: A longitudinal prospective study","volume":"10","author":"Naaber","year":"2021","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_190","doi-asserted-by":"crossref","unstructured":"Daian e Silva, D.S.D.O., and da Fonseca, F.G. (2021). The Rise of Vectored Vaccines: A Legacy of the COVID-19 Global Crisis. Vaccines, 9.","DOI":"10.3390\/vaccines9101101"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1056\/NEJMp2005630","article-title":"Developing Covid-19 Vaccines at Pandemic Speed","volume":"382","author":"Lurie","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): A blinded, multicentre, randomised, controlled, phase 2 trial","volume":"398","author":"Munro","year":"2021","journal-title":"Lancet"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","article-title":"COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses","volume":"586","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"n3011","DOI":"10.1136\/bmj.n3011","article-title":"Covid-19: Antibody boost after third dose varies greatly by vaccine, study finds","volume":"375","author":"Mahase","year":"2021","journal-title":"BMJ"},{"key":"ref_195","doi-asserted-by":"crossref","unstructured":"Hansen, C.H., Schelde, A.B., Moustsen-Helm, I.R., Emborg, H.-D., Krause, T.G., M\u00f8lbak, K., and Valentiner-Branth, P. (2021). Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study. medRxiv.","DOI":"10.1101\/2021.12.20.21267966"},{"key":"ref_196","doi-asserted-by":"crossref","unstructured":"Lu, L., Mok, B.W.-Y., Chen, L., Chan, J.M.-C., Tsang, O.T.-Y., Lam, B.H.-S., Chuang, V.W.-M., Chu, A.W.-H., Chan, W.-M., and Ip, J.D. (2021). Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients. medRxiv.","DOI":"10.1101\/2021.12.13.21267668"},{"key":"ref_197","doi-asserted-by":"crossref","unstructured":"Liu, L., Iketani, S., Guo, Y., Chan, J.F.-W., Wang, M., Liu, L., Luo, Y., Chu, H., Huang, Y., and Nair, M.S. (2021). Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2. bioRxiv.","DOI":"10.1101\/2021.12.14.472719"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1056\/NEJMc2119912","article-title":"SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination","volume":"386","author":"Pajon","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_199","doi-asserted-by":"crossref","unstructured":"D\u2019amelio, R., Asero, R., Cassatella, M.A., Lagan\u00e0, B., Lunardi, C., Migliorini, P., Nisini, R., Parronchi, P., Quinti, I., and Racanelli, V. (2021). Anti-COVID-19 vaccination in patients with autoimmune-autoinflammatory disorders and primary\/secondary immunodeficiencies: The position of the task force on behalf of the italian immunological societies. Biomedicines, 9.","DOI":"10.3390\/biomedicines9091163"},{"key":"ref_200","first-page":"674","article-title":"Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged \u226565 Years\u2014United States, January\u2013March 2021","volume":"70","author":"Tenforde","year":"2021","journal-title":"MMWR Recomm. Rep."},{"key":"ref_201","unstructured":"Naveen, R., Parodis, I., Joshi, M., Sen, P., Lindblom, J., Agarwal, V., Lilleker, J.B., Tan, A.L., and Nune, A. (2022). COVID-19 vaccination in autoimmune diseases (COVAD) study: Vaccine safety and tolerance in rheumatoid arthritis. Rheumatology."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12929-020-00695-2","article-title":"Coronavirus vaccine development: From SARS and MERS to COVID-19","volume":"27","author":"Li","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1007\/s43440-022-00425-5","article-title":"Recent Review of COVID-19 Management: Diagnosis, Treatment and Vaccination","volume":"74","author":"Chavda","year":"2022","journal-title":"Pharmacol. Rep."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/978-1-4939-9065-8_9","article-title":"Current use of adenovirus vectors and their production methods","volume":"1937","author":"Sayedahmed","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.tibtech.2020.12.006","article-title":"Build a Sustainable Vaccines Industry with Synthetic Biology","volume":"39","author":"Kitney","year":"2021","journal-title":"Trends Biotechnol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines\u2014A new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_207","first-page":"2875","article-title":"Pre-existing immunity against Ad vectors","volume":"10","author":"Kobinger","year":"2015","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_208","doi-asserted-by":"crossref","unstructured":"Dangi, T., Sanchez, S., Lew, M.H., Visvabharathy, L., Richner, J., Koralnik, I.J., and Penaloza-MacMaster, P. (2022). Pre-existing immunity modulates responses to mRNA boosters. bioRxiv.","DOI":"10.1101\/2022.06.27.497248"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.tibs.2021.03.002","article-title":"COVID-19 Vaccines Based on Adenovirus Vectors","volume":"46","author":"Hasanpourghadi","year":"2021","journal-title":"Trends Biochem. Sci."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1126\/science.aax0194","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Hwang","year":"2020","journal-title":"Science"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/2\/432\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:33:59Z","timestamp":1760121239000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/2\/432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,13]]},"references-count":210,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["vaccines11020432"],"URL":"https:\/\/doi.org\/10.3390\/vaccines11020432","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,13]]}}}